Tailored Radiotherapy After Chemotherapy Reduces Breast Cancer Recurrence Risk

New ten-year findings demonstrate that breast cancer recurrence rates remain low even after a decade when radiotherapy is tailored to a patient’s individual risk level following chemotherapy and surgery, potentially reducing side effects for many patients.

Understanding the Study Findings

Research presented at the 15th European Breast Cancer Conference (EBCC15) in Barcelona reveals that adjusting radiotherapy treatment based on the presence of residual cancer cells in lymph nodes after initial chemotherapy and surgery can significantly impact patient outcomes. For women showing no remaining cancer in their lymph nodes, a minimal or even no radiotherapy approach was utilized.

How Radiotherapy is Being Tailored

Traditionally, radiotherapy is used to reduce the risk of breast cancer recurrence, particularly after surgery, and when cancer is detected in the lymph nodes. This study explored whether radiotherapy could be scaled back for patients exhibiting a positive response to chemotherapy prior to surgery. The research, led by Dr. Fleur Mauritz, a radiation oncologist in training at Maastro, Maastricht Radiation Oncology Institute in The Netherlands, focused on this possibility.

Study Details and Results

The study encompassed 848 patients treated at 17 cancer centers across The Netherlands between 2011, and 2015. Results indicate low recurrence rates across different risk groups:

• Low-Risk Group: 2.4% (7 out of 291 patients) experienced recurrence.
• Intermediate-Risk Group: 3.2% (12 out of 370 patients) experienced recurrence.
• High-Risk Groups: Recurrence rates were also relatively low in high-risk groups, though specific numbers were not detailed in available sources.

Benefits of Tailored Treatment

Scaling back radiotherapy, when appropriate, can lead to a significant reduction in side effects for patients. This approach allows for a more personalized treatment plan, balancing the need to control recurrence risk with the desire to minimize the impact on a patient’s quality of life.

Implications for Future Treatment

These findings suggest that a more nuanced approach to radiotherapy planning is possible, potentially allowing many patients to safely receive less treatment without compromising their long-term prognosis. Further research is ongoing to refine risk assessment and optimize treatment strategies.

Key Takeaways

• Radiotherapy can be safely tailored to individual patient risk after chemotherapy and surgery.
• Patients with no remaining cancer in lymph nodes may require minimal or no radiotherapy.
• Tailored treatment can reduce side effects without increasing recurrence risk.
• Ten-year recurrence rates remain low even with reduced radiotherapy in appropriate cases.

Sources:

Medscape, Medicalxpress, Brightsurf